Invitrogen to Validate Reagents on Tecan, BMG Labtech Platforms | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen said Tuesday that it has inked two new agreements, one with Tecan and another with BMG Labtech, to study and validate its reagents with the companies’ microplate instruments.
 
Under the terms of both of the agreements, announced separately, Invitrogen will work with the companies to develop and promote joint applications to market to pharmaceutical companies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.